MXC: $0.041
What We Grow

MGC Pharmaceutical’s Botanic Division works with numerous agricultural sites to meet growing demand worldwide, together with exploration into breeding and genetics with prominent establishments and academia. Dedicated to the growth of new genetics, focusing on certain medical indications, this division is where all GMP raw material for our clinical studies is created for patient treatment all over the globe.

Research and Development
  • Improving and stabilising MGC Pharma’s genetic bank in order to match treatments and indications, and to ensure our ability to seamlessly create products of identical high quality worldwide, to be fed into our pipelines.
  • University of Ljubljana botanic research project set to commence in order to develop new genetic strains.
  • Collaboration with Academy of Science, Czech Republic, on multiple strain grows.
Our cultivation sites
MGC Pharma is actively securing multiple cultivation sites to support an efficient and cost effective supply chain across key global markets.
Our strategic focus is in three major geographical areas of engagement: Europe, North America and Australasia
Business Development

We will continue to harvest the product in Slovenia and Czech Republic, and utilize the raw material at our production facility, as well as provide the product globally. Our product is delivered to our Innovation and Derma departments to produce best in class products for sale and distribution around the world.

Projects
  • Successful harvests at Slovenian and Czech growing sites completed, with positive results. Next harvest yielding product viable for pharmaceutical API and cosmetics.
  • Biotechnical academy in Slovenia focused on producing new strains and IP for MGC Pharma.
Partners
  • Commencing global collaborations with various revenue models, including licensing proprietary MGC Pharma IP to collaborative partners in various geographies.
view all partners